About Lodo Therapeutics
Lodo Therapeutics is a company based in New York (United States) founded in 2015 by Sean Brady was acquired by Zymergen in May 2021. Lodo Therapeutics has raised $19.87 million across 1 funding round from investors including AbbVie, Lilly and ARE. The company has 24 employees as of December 31, 2022. Lodo Therapeutics has completed 2 acquisitions, including Conifer Point and Hibiskus. Lodo Therapeutics offers products and services including AI Models, Data Generation, and Lab Automation. Lodo Therapeutics operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Symbiomix Therapeutics and SpyBiotech, among others.
- Headquarter New York, United States
- Employees 24 as on 31 Dec, 2022
- Founders Sean Brady
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lodo Therapeutics Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.87 M (USD)
in 1 rounds
-
Latest Funding Round
$19.87 M (USD), Series A
Jan 04, 2017
-
Investors
AbbVie
& 13 more
-
Employee Count
24
as on Dec 31, 2022
-
Investments & Acquisitions
Conifer Point
& 1 more
-
Acquired by
Zymergen
(May 28, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lodo Therapeutics
Lodo Therapeutics offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation.
Provides fine-tuning for AI in biotechnology research
Generates high-quality datasets for R&D applications
Offers hardware and software for efficient lab processes
People of Lodo Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Product Management Team
1 people
Finance and Accounting
1 people
CTO Team
1 people
Unlock access to complete
Funding Insights of Lodo Therapeutics
Lodo Therapeutics has successfully raised a total of $19.87M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.87 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lodo Therapeutics
Lodo Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Lilly and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Economic growth is supported via family-backed investments in New York.
|
Locked | Locked | Locked | |
|
VC firm funding companies in the US
|
Locked | Locked | Locked |
Investor details for Lodo Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lodo Therapeutics
Lodo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Conifer Point and Hibiskus.
Investment portfolio details for Lodo Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule therapeutics for cancer are developed by Hibiskus.
|
Locked | Locked | 2017 | Locked | |
|
New drugs are developed using custom fragment-based design software.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Lodo Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lodo Therapeutics
Detailed financials for Lodo Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lodo Therapeutics Comparisons
Peer comparison for Lodo Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lodo Therapeutics
Lodo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Symbiomix Therapeutics and SpyBiotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of Lodo Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lodo Therapeutics
Complete news archive for Lodo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lodo Therapeutics
Lodo Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Lodo Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Lodo Therapeutics is a funded company, having raised a total of $19.87M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Lodo Therapeutics is 24.
Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.
Lodo Therapeutics's top competitors include Insmed, MaaT Pharma and Basilea.
Lodo Therapeutics offers AI Models, Data Generation, and Lab Automation.
Lodo Therapeutics has made 2 acquisitions, including Conifer Point, and Hibiskus.
Lodo Therapeutics has 14 investors. Key investors include AbbVie, Lilly, ARE, New York State, and Zymergen.